Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

IVVD

+ Watchlist+ Portfolio

Invivyd, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.51
52-Week Range
$0.46 – $3.01
Market Cap
$139.09M
P/E (TTM)
—
EPS (TTM)
-0.38
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.92
PEG Ratio
—
Return on Equity
-107.03%
Return on Assets
-52.70%
Gross Margin
92.60%
Operating Margin
-224.42%
Profit Margin
-214.77%
Current Ratio
5.51
Debt/Equity
0.05
Total Debt
$8.25M
Free Cash Flow
$-88.70M
Revenue Growth
17.70%
Earnings Growth
—
Enterprise Value
$20.94M

Market Snapshot

About

Invivyd, Inc. is a biopharmaceutical company dedicated to protecting vulnerable populations from serious viral infectious diseases. The company focuses on developing antibody-based therapies for infectious diseases, with an initial emphasis on COVID-19 and influenza. Invivyd's platform combines expertise in antibody discovery, engineering, and clinical development to create potent and durable antiviral therapies. The company was spun out from AstraZeneca's long-acting antibody program and continues to advance next-generation antibody treatments designed to address evolving viral threats.